Company: AEMD
Filing Date: 2025-06-26
Form Type: 10-K
Source: 0001683168-25-004780
Chunk: 1305

Company: AETHLON MEDICAL INC
Filing Date: 2025-06-26
Form: 10-K
Item: Item 9
Chunk 1305
---
 - $7,500 (not applicable to the chair) and Nominating Committee member - $5,000 (not applicable to the chair).
Additionally, the Chairperson of the Board of Directors will receive an additional annual board retainer fee of $30,000.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
AND RELATED STOCKHOLDER MATTERS 

The following table sets forth
information as of March 31, 2025, with respect to the ownership of our common stock, by (i) each person known by us to be the beneficial
owner of more than five percent (5%) of the outstanding shares of each class of our capital stock, (ii) each of our directors and director
nominees, (iii) each of our executive officers, and (iv) all of our named executive officers and directors as a group. As of such date,
we had 2,585,316 shares of our common stock issued and outstanding, after adjustment for the 1-for-8 reverse stock split effective as
of the close of business on June 6, 2025 with an effective trading date of June 9, 2025. We believe that each individual or entity named
has sole investment and voting power with respect to shares of common stock indicated as beneficially owned by them, subject to community
property laws where applicable, except where otherwise noted.

Unless otherwise indicated,
the address for each person listed in the table below is c/o Aethlon Medical, Inc., 11555 Sorrento Valley Road, Suite 203, San Diego,
CA 92121.

    NAME OF BENEFICIAL OWNER 
    NUMBER OF SHARES BENEFICIALLY OWNED(1)  
    PERCENT OF SHARES BENEFICIALLY OWNED(2) 
  
    Greater than 5% Stockholders 

    Armistice Capital, LLC 
     180,758(3) 
     7% 
  
    Ikarian Capital, LLC 
     153,660(4) 
     6% 
  
    Directors and Named Executive Officers 

    James B. Frakes, Chief Executive Officer, Chief Financial Officer and Director 
     2,805(5) 
     * 
  
    Edward G. Broenniman, Chairman and Director 
     4,887(6) 
     * 
  
    Chetan S. Shah, M.D., Director 
     3,923